Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Down syndrome screening and diagnosis practices in Europe, United States, Australia, and New Zealand from 1990–2021

Abstract

Antenatal screening and diagnostic testing for Down syndrome has greatly advanced over the past 30 years. The goal of this manuscript is to provide a review of the availability and accessibility of prenatal services and selective termination policies across Europe, Australia, New Zealand, and the United States for the period 1990–2021. We collected data from academic peer-reviewed journals, governmental documents, not-for-profit organizations, correspondence with experts, and other online sources without language restrictions. Prenatal screening services from 1990–2021 became increasingly available across countries, enabling expectant couples the opportunity to gain more accurate information earlier in the pregnancy before assuming the risk associated with more invasive techniques like CVS or amniocentesis. Many countries also began adopting prenatal screening as a qualification for prenatal diagnosis. As of 2021, at least 76.9% of countries offered full coverage for diagnostic testing for Down syndrome from government funding. Abortion coverage for a Down syndrome diagnosis was covered fully by government funding in 52.4% of countries in 1990, increasing to 73.8% in 2021. Understanding the changing landscape of prenatal services builds the foundation for future investigation into social policies that affect the prevalence of Down syndrome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Government-provided coverage of abortion for Down syndrome, 1990–2021.
Fig. 2: Government-provided coverage of abortion for Down syndrome in 2021.
Fig. 3: Government-provided coverage of prenatal screening for Down syndrome, 1990–2021.
Fig. 4: Government-provided coverage of prenatal screening for Down syndrome in 2021.
Fig. 5: Government-provided coverage of amniocentesis or CVS for Down syndrome, 1990–2021.
Fig. 6: Government-provided coverage of amniocentesis or CVS for Down syndrome in 2021.

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article and its Supplementary Information files.

Code availability

All data generated or analyzed during this study are included in this published article and its Supplementary Information files.

References

  1. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol. 2007;110:1459–67.

    Article  Google Scholar 

  2. Norwitz ER, Levy B. Noninvasive prenatal testing: the future is now. Rev Obstet Gynecol. 2013;6:48–62.

    PubMed  PubMed Central  Google Scholar 

  3. Abortion Legislation In Europe: Updated January 2012 [Internet]. IPPF European Network; 2012 [cited 2021 Jul 15]. Available from: https://europe.ippf.org/resource/abortion-legislation-europe.

  4. Special Report: Prenatal Screening Policies in Europe [Internet]. EUROCAT Central Registry, University of Ulster; 2010 [cited 2021 Jul 9]. Available from: https://www.orpha.net/actor/Orphanews/2010/doc/Special-Report-Prenatal-Screening-Policies.pdf.

  5. de Graaf G, Skladzien E, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Australia and New Zealand. Genet Med. 2022;24:2568–77.

    Article  PubMed  Google Scholar 

  6. de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A. 2015;167:756–67.

    Article  Google Scholar 

  7. de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Europe. Eur J Hum Genet. 2021;29:402–10.

    Article  PubMed  Google Scholar 

  8. World Population Prospects - Population Division - United Nations [Internet]. [cited 2022 Mar 29]. Available from: https://population.un.org/wpp/Download/Standard/Population/.

  9. Access Denied: Origins of the Hyde Amendment and Other Restrictions on Public Funding for Abortion [Internet]. American Civil Liberties Union. [cited 2021 Jul 16]. Available from: https://www.aclu.org/other/access-denied-origins-hyde-amendment-and-other-restrictions-public-funding-abortion.

  10. Abortion and Medicare - Children by Choice [Internet]. [cited 2021 Oct 11]. Available from: https://www.childrenbychoice.org.au/factsandfigures/abortionandmedicare.

  11. Interactive NV. Decide: National Abortion Telehealth Service, FAQ [Internet]. Decide – National Abortion Telehealth Service. [cited 2022 May 17]. Available from: (https://www.nvinteractive.com/) https://www.decide.org.nz/en/faqs/.

  12. 2021. The Hyde Amendment and Coverage for Abortion Services [Internet]. KFF. 2021 [cited 2021 Jul 16]. Available from: https://www.kff.org/womens-health-policy/issue-brief/the-hyde-amendment-and-coverage-for-abortion-services/.

  13. van der Steen SL, Houtman D, Bakkeren IM, Galjaard RJH, Polak MG, Busschbach JJ, et al. Offering a choice between NIPT and invasive PND in prenatal genetic counseling: the impact of clinician characteristics on patients’ test uptake. Eur J Hum Genet. 2019;27:235–43.

    Article  PubMed  Google Scholar 

  14. Crombag NM, Page-Christiaens GC, Skotko BG, de Graaf G. Receiving the news of Down syndrome in the era of prenatal testing. Am J Med Genet A. 2020;182:374–85.

    Article  PubMed  Google Scholar 

  15. Skotko BG. Prenatally diagnosed Down syndrome: mothers who continued their pregnancies evaluate their health care providers. Am J Obstet Gynecol. 2005;192:670–7.

    Article  PubMed  Google Scholar 

  16. Crombag NM, Vellinga YE, Kluijfhout SA, Bryant LD, Ward PA, Iedema-Kuiper R, et al. Explaining variation in Down’s syndrome screening uptake: comparing the Netherlands with England and Denmark using documentary analysis and expert stakeholder interviews. BMC Health Serv Res. 2014;14:437.

    Article  PubMed  PubMed Central  Google Scholar 

  17. de Graaf G, Buckley F, Skotko B. People living with Down syndrome in the USA: BIRTHS AND POPULATION [Internet]. 2022 [cited 2022 Apr 22]. Available from: https://go.downsyndromepopulation.org/usa-factsheet.

  18. Kahneman D, Thaler R. Anomalies: Utility Maximization and Experienced Utility. J Econ Perspect. 2006;20:221–34.

  19. Allyse M, Aypar U, Bonhomme N, Darilek S, Dougherty M, Farrell R, et al. Offering prenatal screening in the age of genomic medicine: a practical guide. J Women’s Health 2002. 2017;26:755–61.

    Article  Google Scholar 

  20. Skotko B, Bedia RC. Continuación del embarazo después de un diagnóstico prenatal de síndrome de Down. Estudio de cuatro casos. Diagn Trat Prenat. 2006;17:189–92.

    Google Scholar 

Download references

Acknowledgements

We would like to thank and acknowledge Dr. Anila Laku from Mother Teresa Hospital & Emanuela Zaimi, MA., from Down Syndrome Albania Foundation for their aid in finding information on prenatal services in Albania; Marge Kato from Down Syndrome Association Estonia for her information on prenatal services in Estonia; Yuliya Dmytrenko from Ukraine Down Syndrome Organization for her information on prenatal services in Ukraine; Dr. Ellen Skladzien from Down Syndrome Australia and Dr. Melody Menezes Bsc, GDipGenetCouns, Ph.D., MHGSA from Monash Ultrasound for Women for their information on prenatal services in Australia; Zandra Vaccarino, National Executive Officer of the New Zealand Down Syndrome Association (NZDSA); Kate Alvrez from Family Planning New Zealand for her information on prenatal services in New Zealand; and Maria-Madalina Turza, President, European Centre for the Rights of Children with Disabilities for her information on prenatal services in Romania.

Funding

No funding was received for the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: GdG, HCW, PvC, FB, BGS; Data curation: HCW; Formal analysis: HCW; Funding Acquisition: n/a; Investigation: HCW; Methodology: HCW; Project Administration: HCW, BGS; Resources: n/a.; Software: HCW; Supervision: GdG, PvC, FB, BGS; Validation: HCW; Visualization: HCW: Writing-original draft: HCW, BGS; Writing-review & editing: GdG, HCW, PvC, FB, BGS.

Corresponding author

Correspondence to Brian G. Skotko.

Ethics declarations

Competing interests

Dr. Skotko occasionally consults on the topic of Down syndrome through Gerson Lehrman Group. He receives remuneration from Down syndrome non-profit organizations for speaking engagements and associated travel expenses. Dr. Skotko receives annual royalties from Woodbine House, Inc., for the publication of his book, Fasten Your Seatbelt: A Crash Course on Down Syndrome for Brothers and Sisters. Within the past two years, he has received research funding from F. Hoffmann-La Roche, Inc. and LuMind Research Down Syndrome Foundation to conduct clinical trials for people with Down syndrome. Dr. Skotko is occasionally asked to serve as an expert witness for legal cases where Down syndrome is discussed. Dr. Skotko serves in a non-paid capacity on the Honorary Board of Directors for the Massachusetts Down Syndrome Congress and the Professional Advisory Committee for the National Center for Prenatal and Postnatal Down Syndrome Resources. Dr. Skotko has a sister with Down syndrome. Dr. de Graaf had a daughter with DS, who passed away in 2005 at the age of 15. He works as science and education officer at the Dutch Down Syndrome Foundation, a nonprofit organization. Frank Buckley serves as CEO of Down Syndrome Education International and Down Syndrome Education USA, nonprofits engaged in research and support for young people with Down syndrome. He had a sister with Down syndrome, who passed away in 2020. Dr. van Casteren has a daughter with Down syndrome. Henry Wilmot declares no conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilmot, H.C., de Graaf, G., van Casteren, P. et al. Down syndrome screening and diagnosis practices in Europe, United States, Australia, and New Zealand from 1990–2021. Eur J Hum Genet 31, 497–503 (2023). https://doi.org/10.1038/s41431-023-01330-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41431-023-01330-y

This article is cited by

Search

Quick links